HPV vaccination in women treated for Cervical Intraepithelial Neoplasia grade 2 or 3: evidence-based recommendation from the Multisociety Italian Guidelines for cervical cancer prevention

Objective: Women treated for Cervical Intraepithelial Neoplasia (CIN) grade 2 or 3 are at increased risk of CIN and cervical cancer. Human Papillomavirus (HPV) vaccination is effective in preventing CIN in women who are not infected by HPV. Some studies suggested that vaccination may reduce the risk of CIN2 or 3 in women treated for CIN. A working group including all Italian scientific societies involved in tackling cervical cancer developed a recommendation on vaccination against HPV for women treated for CIN2 or CIN3. Data sources, methods of study selection: The group conducted a systematic review of the literature published from January 2006 to May 2019. Evidence on safety outcomes was retrieved by a recent Cochrane Review on vac-cination in the general population. To develop the final recommendation, evidences were appraised and integrated by a Panel of Experts using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision framework. Tabulation, integration and results: Six eligible studies were included. Four were RCTs and two were cohort studies, with different timing of vaccination. An additional study, published in October 2019, was taken into consideration after external review. A reduction of 70% CIN2+ in the treatment group was estimated; the vaccine was considered safe. Conclusion: The working group recommends the use of HPV vaccination in women treated for CIN2 or 3. The strong recommendation is based on large estimated desirable effects and trivial anticipated undesirable effects (moderate certainty of evidence), negligible costs and savings (no studies included), and a positive judgment in terms of feasibility, acceptability, and impact on equity.

Cervical cancer; Screening; Human papillomavirus; Vaccination

[1] Osservatorio Nazionale Screening (ONS). Rapporto Nazionale. 2017. Available at: https://www.osservatorionazionalescreening .it/sites/default/files/allegati/ons%20rapporto%202017.pdf (Accessed: 28 March 2021).

[2] Gruppo Tecnico Nazionale PASSI. I dati per l’Italia: lo screening cervicale. 2015–2018. Available at: https://www.epicentro.iss.it /passi/dati/ScreeningCervicale (Accessed: 28 March 2021).

[3] Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vac-cination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews. 2018; 5: CD009069.

[4] Strander B, Hällgren J, Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. British Medical Journa. 2014; 348: f7361.

[5] Rebolj M, Helmerhorst T, Habbema D, Looman C, Boer R, van Rosmalen J, et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. British Medical Journal. 2013; 345: e6855.

[6] Prime 6 Raccomandazioni GISCI per il follow up post trattamento CIN2 e CIN3 riportate nel capitolo 5 del: gruppo trasversale GISCi sul follow up dopo trattamento. Utilizzo del test HPV-HR nel triage delle ASC-US, delle LSIL in donne con più di 35 anni, nel follow-up delle donne con citologia ASC-US+ dopo un appro-fondimento di secondo livello negativo per CIN2+ e nel follow-up dopo trattamento delle lesioni CIN2-3: aggiornamento 2018. 2018. Available at: http://gisci.it/documenti/documenti_gisci/U tilizzo_test_HPV-HR_2018_def2.pdf (Accessed: 28 March 2021).

[7] Onuki M, Matsumoto K, Sakurai M, Ochi H, Minaguchi T, Satoh T, et al. Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis. Journal of Gynecologic Oncology. 2016; 27: e3.

[8] Arbyn M, Anttila A, Jordan J, Schenck U, Ronco G, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Annals of Oncology. 2010; 21: 448–458.

[9] Anttila A, Arbyn A, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Second edition, Supplements. (pp. XIII–XXIV). Luxembourg: Office for Official Publications of the European Union. 2015.

[10] Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiologia E Prevenzione. 2012; 36: e1–72. (In Italian)

[11] Italian Ministry of Health. Screening oncologici. Raccomandazioni per la pianificazione e l’esecuzione degli screening di popolazione per la prevenzione del cancro della mammella, del cancro della cervice uterina e del cancro del colon retto. 2006. Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_774_alle gato.pdf (Accessed: 28 March 2021).

[12] Ghini I, Venturelli F, Rossi PG, Iossa A, Garutti P. HPV vaccination and the risk of clinical disease recurrence in women treated for high-grade cervical intraepithelial neoplasia (CIN2 or CIN3). 2019. Available at: https://www.crd.york.ac.uk/prospero/displa y_record.php?ID=CRD42019135870 (Accessed: 28 March 2021).

[13] Venturelli F on behalf of the Multisociety Italian Guidelines for cervical cancer prevention Working Group. Developing evidencebased Multisociety Italian Guidelines for cervical cancer prevention: rationale, methods, and development process. European Journal of Gynaecological Oncology. 2021; 42: 634–642.

[14] Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology. 2011; 64: 395–400.

[15] Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. British Medical Journal. 2017; 353: i2089.

[16] GRADEpro GDT online platform. McMaster University and Ev-idence Prime Inc. 2020. Available at: https://gradepro.org/ (Ac-cessed: 28 March 2021).

[17] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal. 2019; 366: I4898.

[18] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-i: a tool for assessing risk of bias in non-randomised studies of interventions. British Medical Journal. 2017; 355: i4919.

[19] Schünemann HJ, Brożek J, Guyatt G, and Andrew Oxman, et al. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 2013. Available at: https://gdt.gradepro.org/app/handbook/handbook.html (Accessed: 28 March 2021).

[20] Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Completing ‘summary of findings’ tables and grading the certainty of the evidence. Cochrane Handbook for Systematic Reviews of Interventions. 2019; 170: 375–402.

[21] Schünemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. Journal of Clinical Epidemiology. 2017; 81: 101–110.

[22] Istituto Superiore di Sanità. Sistema Nazionale Linee Guida dell’Istituto Superiore di Sanità. 2001. Available at: https://snlg .iss.it/ (Accessed: March 28 2021).

[23] Pieralli A, Bianchi C, Auzzi N, Fallani MG, Bussani C, Fambrini M, et al. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease. Archives of Gynecology and Obstetrics. 2019; 298: 1205–1210.

[24] Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecologic Oncology. 2013; 130: 264–268.

[25] Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecologic Oncology. 2018; 151: 229–234.

[26] Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. British Medical Journal. 2012; 344: e1401.

[27] Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: posthoc analysis from a randomized controlled trial. International Journal of Cancer. 2016; 139: 2812–2826.

[28] Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. American Journal of Obstetrics and Gynecology. 2017; 215: 212.e1–212.e15.

[29] Sand FL, Kjaer SK, Frederiksen K, Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. International Journal of Cancer. 2020; 147: 641–647.

[30] Intercent-ER. Agenzia per lo sviluppo dei mercati telematici. Vaccino HPV Gardasil 9. Regione Emilia-Romagna. 2019. Available at: https://intercenter.regione.emilia-romagna.it/serv izi-pa/convenzioni/convenzioni-scadute-e-o-esaurite/2017/va ccino-hpv-gardasil-9 (Accessed: 1 June 2019).

[31] Intercent-ER. Agenzia per lo sviluppo dei mercati telematici. Vaccini vari ad uso umano 2016/2018 “es-clusivi”. Regione Emilia-Romagna. 2019. Available at: https://intercenter.regione.emilia-romagna.it/servizi-pa/co nvenzioni/convenzioni-scadute-e-o-esaurite/2016/vaccini-vari- ad-uso-umano-2016-2018-201cesclusivi201d/vaccini-vari-ad-uso-umano-2016-2018-201cesclusivi201d (Accessed: 1 June 2019).

[32] Petrelli A, Giorgi Rossi P, Francovich L, Giordani B, Di Napoli A, Zappa M, et al. Geographical and socioeconomic differences in uptake of Pap test and mammography in Italy: results from the National Health Interview Survey. British Medical Journal Open. 2019; 8: e021653.

[33] Carrozzi G, Sampaolo L, Bolognesi L, Sardonini L, Bertozzi N, Giorgi Rossi P, et al. Cancer screening uptake: association with individual characteristics, geographic distribution, and time trends in Italy. Epidemiologia E Prevenzione. 2017; 39: 9–18.

[34] Venturelli F, Baldacchini F, Campari C, Perilli C, Pascucci MG, Finarelli AC, et al. Association between mothers’ screening uptake and daughters’ HPV vaccination: a quasi-experimental study on the effect of an active invitation campaign. British Medical Journal Open. 2018; 7: e016189.

[35] Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Gar-cia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease. 2020; 24: 102–131.

[36] Public Health England. Guidance Cervical screening: programme and colposcopy management. NHS cervical screening (CSP) programme. 2020. Available at: https://www.gov.uk/government/publications/cervical-scr eening-programme-and-colposcopy-management (Accessed: 28 March 2021).

[37] SICPCV Raccomandazioni SICPCV 2019. Italian Society for Colposcopy and Cervico-Vaginal Pathology. 2019. Available at http://www.colposcopiaitaliana.it/interna04.asp.htm (Accessed: 28 March 2021).

[38] Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. British Medical Journal. 2016; 354: i3633.

[39] Del Pino M, Martí C, Torras I, Henere C, Munmany M, Marimon L, et al. HPV vaccination as adjuvant to conization in women with cervical intraepithelial neoplasia: a study under real-life conditions. Vaccines. 2020; 8: 245.

[40] Karimi-Zarchi M, Allahqoli L, Nehmati A, Kashi AM, Taghipour-Zahir S, Alkatout I. Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial. British Medical Journal Public Health. 2020; 20: 274.

[41] Lu P, Byrd KK, Murphy TV, Weinbaum C. Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009. Vaccine. 2012; 29: 7049–7057.

[42] François G, Hallauer J, Van Damme P. Hepatitis B vaccination: how to reach risk groups. Vaccine. 2003; 21: 1–4.

[43] Saslow D, Andrews KS, Manassaram‐Baptiste D, Smith RA, Fontham ETH. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA: A Cancer Journal for Clinicians. 2020; 70: 274–280.

[44] Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: up-dated recommendations of the advisory committee on immuniza-tion practices. Morbidity and Mortality Weekly Report. Morbidity and Mortality Weekly Report. 2019; 68: 698–702.

[45] European Centre for Disease Prevention and Con-trol. Introduction of HPV vaccines in EU countries—an update. Stockholm: ECDC; 2012. Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publ ications/Publications/20120905_GUI_HPV_vaccine_update.pdf (Accessed: 28 March 2021).

[46] Martínez-Gómez X, Curran A, Campins M, Alemany L, Rodrigo-Pendás J, Borruel N, et al. Multidisciplinary, evidence-based con-sensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. Eurosurveillance. 2019; 24: 1700857.

[47] Schiller-Frühwirth I, Wilbacher I. HPV vaccination after treatment for high-grade cervical intraepithelial neoplasia. Österreichische Sozialversicherung. 2019. Available at: https://www.sozialversicherung.at/cdscontent/load?contentid= 10008.723534&version=1570024134 (Accessed: 28 March 2021).

[48] Joura EA, Kyrgiou M, Bosch FX, Kesic V, Niemenen P, Redman CW, et al. Human papillomavirus vaccination: the ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. European Journal of Cancer. 2019; 116: 21–26.

[49] Ghelardi A. Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 (HOPE9). HOPE9 Study protocol. 2019. Available at: https://clinicaltrials.gov/ct2/show/study/NCT03848039 (Accessed: 28 March 2021).

[50] Kyrgiou M. Nonavalent Prophylactic HPV Vaccine (GAR-DASIL9) After Local Conservative The NOVEL Trial (NOVEL). NOVEL study protocol. 2019. Available at: https://clinicaltrials.g ov/ct2/show/NCT03979014 (Accessed: 28 March 2021).